Biosimilars in Puerto Rico: Different Challenges, New Opportunities?
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Biosimilars in Puerto Rico: Different Challenges, New Opportunities?
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
Presented at: Specialty Pharmaceutical Summit 2025 SPS Puerto Rico
Summit Directors:
Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC, FACHE | Baptist Health South Florida
Bhavesh Shah, RPh, BCOP | Boston Medical Center
Biosimilars in Puerto Rico: Different Challenges, New Opportunities?
Moderator: Jorge J. Garcia, PharmD, MS, MHA, MBA, FACCC,FACHE| Baptist Health South Florida
Panel: Orlando Rivera Perez, PharmD | MSO ofPuerto Rico; Belmarie Palen, PharmD, CSP | AxiumHealthcare Puerto Rico; Gladiany Ramos-Marrero, PharmD, RPh, CSP | MCS Puerto Rico; Eric Frontera Zayas, PharmD | PharmPix
The panel discussed the economic and clinical potential of biosimilars in Puerto Rico, emphasizing education, accesschallenges, and interchangeability issues, particularly with adalimumab conversions. They highlighted the need for ongoing provider education, academic detailing, and better supply chain management to maximize adoption and patientbenefit.